Personalized Immunotherapy May Be Effective Ovarian Cancer Treatment, Study Finds

Personalized Immunotherapy May Be Effective Ovarian Cancer Treatment, Study Finds
A new method that identifies and expands T-cells with high tumor-killing activity is a promising approach against ovarian cancer, a study shows. Findings could be used to develop a personalized, cell-based immunotherapy that effectively treats ovarian cancer, which has proven resistant to current immunotherapies. Using this method, researchers found that T-cells that are isolated from tumors have better anti-cancer properties than their counterparts isolated from the bloodstream. The study, “Sensitive and frequent identification of high avidity neo-epitope specific CD8+ T cells in immunotherapy-naive ovarian cancer,” was published in the journal Nature Communications. Tumors with cells that are highly mutated are usually more responsive to immunotherapies because the rate of mutations in these tumors leads to the formation of abnormal, mutated proteins — neoantigens – that may be recognized by the immune system. A subset of effector immune cells called CD8 T-cells can recognize small pieces of neoantigens — called neopitopes — as foreign and orchestrate an immune attack against the cancer cells. The amount of neoepitopes exposed to the immune system, however, varies greatly among patients, even those with the same cancer type. This has impaired the development of antigen-targeting therapies, or immunotherapies. Tumor cells in patients with
Subscribe or to access all post and page content.